Cue Biopharma, Inc. Insider Trading

CUE

Last 12 months

Insiders bought 100K and sold $2.43M on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Executive Officer Shao-Lee Lin sold $1.61M on Aug 13, 7.6% of their stake, outside a plan.

Net open-market

−$2.33M

1 buy · 6 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 3

executives and directors

Last open-market buy

Dec 2025

Dec 30, 2025

Get an email when CUE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 12	Sumita Ray Chief Legal Compliance Officer	SoldNo plan	1,844	$28.05	52K	1.6%	Form 4
Oct 12	Michael Vincent Meluzio VP, Prin. Accounting Officer	SoldNo plan	1,144	$28.05	32K	2.3%	Form 4
Oct 12	Shao-Lee Lin Chief Executive Officer	SoldNo plan 2 parts	11,087	$27.55 average	305K	1.6%	Form 4
Aug 13	Michael Vincent Meluzio VP, Prin. Accounting Officer	SoldNo plan 3 parts	5,628	$30.09 average	169K	10%	Form 4
Aug 13	Sumita Ray Chief Legal Compliance Officer	SoldNo plan 3 parts	8,829	$30.09 average	266K	6.9%	Form 4
Aug 12 – 13	Shao-Lee Lin Chief Executive Officer	SoldNo plan 5 parts	58,258	$27.58 average	$1.61M	7.6%	Form 4
Dec 30, 2025	Pasha Sarraf Director	Bought 5 parts	323,857	$0.31 average	100K	New	Form 4
Dec 16, 2024	Daniel R Passeri Chief Executive Officer	Bought	30,000	$1.03	31K	22%	Form 4

Oct 12No plan
Sumita Ray
Chief Legal Compliance Officer · sold 1,844 at $28.05
52K
1.6% of stake
Oct 12No plan
Michael Vincent Meluzio
VP, Prin. Accounting Officer · sold 1,144 at $28.05
32K
2.3% of stake
Oct 12No plan
Shao-Lee Lin
Chief Executive Officer · sold 11,087 at avg $27.55
305K
1.6% of stake
Aug 13No plan
Michael Vincent Meluzio
VP, Prin. Accounting Officer · sold 5,628 at avg $30.09
169K
10% of stake
Aug 13No plan
Sumita Ray
Chief Legal Compliance Officer · sold 8,829 at avg $30.09
266K
6.9% of stake
Aug 12 – 13No plan
Shao-Lee Lin
Chief Executive Officer · sold 58,258 at avg $27.58
$1.61M
7.6% of stake
Dec 30, 2025
Pasha Sarraf
Director · bought 323,857 at avg $0.31
100K
New position
Dec 16, 2024
Daniel R Passeri
Chief Executive Officer · bought 30,000 at $1.03
31K
22% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CUE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CUE

CompareIntrinsic value

LIFDLftd Partners Inc.

$0.11+0.00%35

VTVTvTv Therapeutics Inc.

$24.03+2.04%40

NRIXNurix Therapeutics Inc.

$15.95-38.23%84

FHTXFoghorn Therapeutics Inc.

$2.10-1.41%40

ETSTEarth Science Tech Inc.

$0.10+0.00%72

SBFMSunshine Biopharma Inc.

$2.65-3.28%40

CELUCelularity Inc.

$0.81-1.00%0

ZOMDFZomedica Corp.

$0.09-1.08%46

Spot a number that looks wrong? Check it in CUE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CUE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.